Lv1
90 积分 2025-11-14 加入
ZHANG P, ZHANG Q, TONG Z, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2023, 24(6): 646-57
5天前
已关闭
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
5天前
已完结
Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis
15天前
已关闭
Leptomeningeal disease and breast cancer: the importance of tumor subtype
1个月前
已完结
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
1个月前
已完结
The Swinging Pendulum of Menopausal Hormone Therapy
1个月前
已关闭
What Systemic Hormone Therapy Black Box Removal Means for Breast Cancer Survivors
1个月前
已关闭
Hypofractionated nodal radiotherapy in breast cancer: time for an updated standard of care?
1个月前
已关闭
Opportunity for Improved Menopausal Hormone Therapy Prescribing
1个月前
已关闭
The Swinging Pendulum of Menopausal Hormone Therapy
1个月前
已关闭
Association between latent tuberculosis infection and assisted reproductive outcomes: a systematic review and meta-analysis
皖公网安备34019202002308
